

(12) International Application Status Report

Received at International Bureau: 15 August 2018 (15.08.2018)

Information valid as of: 01 March 2019 (01.03.2019)

Report generated on: 17 July 2019 (17.07.2019)

(10) Publication number:

WO2019/030268

(43) Publication date:

14 February 2019 (14.02.2019)

(26) Publication language:

English (EN)

(21) Application Number:

PCT/EP2018/071478

(22) Filing Date:

08 August 2018 (08.08.2018)

(25) Filing language:

English (EN)

(31) Priority number(s):

17 306 059.1 (EP)

(31) Priority date(s):

09 August 2017 (09.08.2017)

(31) Priority status:

Priority document received (in compliance with PCT Rule 17.1)

(51) International Patent Classification:

A61K 38/22 (2006.01); A61K 38/26 (2006.01); A61P 1/16 (2006.01)

(71) Applicant(s):

SANOFI [FR/FR]; 54 rue La Boétie 75008 Paris (FR) *(for all designated states)*

(72) Inventor(s):

KANNT, Aimo; c/o Sanofi-Aventis Deutschland GmbH 65926 Frankfurt am Main (DE)

BIELOHUBY, Maximilian; c/o Sanofi-Aventis Deutschland GmbH 65926 Frankfurt am Main (DE)

ELVERT, Ralf; c/o Sanofi-Aventis Deutschland GmbH 65926 Frankfurt am Main (DE)

WAGNER, Michael; c/o Sanofi-Aventis Deutschland GmbH 65926 Frankfurt am Main (DE)

BOSSART, Martin; c/o Sanofi-Aventis Deutschland GmbH 65926 Frankfurt am Main (DE)

HAACK, Torsten; c/o Sanofi-Aventis Deutschland GmbH 65926 Frankfurt am Main (DE)

KEIL, Stephanie; c/o Sanofi-Aventis Deutschland GmbH 65926 Frankfurt am Main (DE)

SEIZ, Werner; c/o Sanofi-Aventis Deutschland GmbH 65926 Frankfurt am Main (DE)

(74) Agent(s):

WEICKMANN & WEICKMANN PARTMBB; Postfach 860 820 81635 München (DE)

(54) Title (EN): GLP-1/GLUCAGON RECEPTOR AGONISTS IN THE TREATMENT OF FATTY LIVER DISEASE AND STEATOHEPATITIS

(54) Title (FR): AGONISTES DU RÉCEPTEUR DE GLP-1/GLUCAGON DANS LE TRAITEMENT DE LA STÉATOSE HÉPATIQUE ET DE LA STÉATOHÉPATITE

(57) Abstract:

(EN): The present invention relates to the medical use of specific GLP-1 /glucagon receptor agonists in the prevention and/or treatment of metabolic liver disease, particularly non-alcoholic fatty liver disease (NAFLD), more particularly non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH) and/or NAFLD-associated liver fibrosis.

(FR): La présente invention concerne l'utilisation médicale d'agonistes spécifiques du récepteur de GLP-1/glucagon dans la prévention et/ou le traitement d'une maladie du foie métabolique, en particulier la stéatose hépatique non alcoolique (NAFLD), notamment le foie gras non alcoolique (NAFL), la stéatohépatite non alcoolique (NASH) et/ou la fibrose hépatique associée à NAFLD.

International search report:

Received at International Bureau: 05 November 2018 (05.11.2018) [EP]

International Report on Patentability (IPRP) Chapter II of the PCT:

Chapter II demand received: 19 February 2019 (19.02.2019)

(81) Designated States:

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

European Patent Office (EPO) : AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG

African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW

Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, RU, TJ, TM

Declarations:

Declaration of inventorship (Rules 4.17(iv) and 51bis.1(a)(iv)) for the purposes of the designation of the United States of America